Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.

Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.

A compound having end groups each having a reactive group that are disposed at both ends respectively, and between the end groups, either or both of a first structure in which an aromatic cyclic group, an ether oxygen, a methylene group, an aromatic cyclic group, a methylene group, an ether oxygen and an aromatic cyclic group are bonded together in this order and a second structure in which an aromatic cyclic group, a methylene group, an ether oxygen, an aromatic cyclic group, an ether oxygen, a methylene group and an aromatic cyclic group are bonded together in this order.

The present disclosure relates to methods and intermediates for the synthesis of certain compounds that inhibit MCL1, for use in the treatment of cancers.

This application pertains to group 5 metal complexes having the structure of Formula I: ##STR00001##
and their potential utility in catalyzing α-alkylation of secondary amine-containing moieties.

This application pertains to group 5 metal complexes having the structure of Formula I: ##STR00001##
and their potential utility in catalyzing α-alkylation of secondary amine-containing moieties.

This application pertains to group 5 metal complexes having the structure of Formula I:

##STR00001##

and their potential utility in catalyzing -alkylation of secondary amine-containing moieties.

This application pertains to group 5 metal complexes having the structure of Formula I:

##STR00001##

and their potential utility in catalyzing -alkylation of secondary amine-containing moieties.

The present disclosure is drawn to polymeric amine synergist compositions. The polymeric amine synergist composition can include a polymeric amine synergist including an aminobenzene modified with a polyether chain connecting to the aminobenzene through an ether linkage. The polymeric amine synergist can be present in a reaction product mixture with either i) an aminophenol, or ii) a carbonate base.

The present disclosure is drawn to polymeric amine synergist compositions. The polymeric amine synergist composition can include a polymeric amine synergist including an aminobenzene modified with a polyether chain connecting to the aminobenzene through an ether linkage. The polymeric amine synergist can be present in a reaction product mixture with either i) an aminophenol, or ii) a carbonate base.